S-1/A: Cingulate Secures $25 Million Equity Financing, Advances ADHD Drug Towards NDA Submission

Cingulate Inc. has entered into a new $25 million committed equity financing agreement with Lincoln Park Capital Fund, LLC to fund its biopharmaceutical pipeline, including the anticipated NDA submission for its lead ADHD candidate, CTx-1301.

Summary

• Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform technology.
• The company's initial focus is on treating Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, with lead product candidates CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD.
• CTx-1301 and CTx-1302 are designed to provide immediate onset, entire active-day duration, eliminate booster doses, minimize rebound symptoms, and offer favorable tolerability.
• The U.S. ADHD treatment market is estimated at over $23 billion as of November 2023, with stimulants accounting for $18.6 billion (88% of prescriptions).
• Cingulate has entered into a new Purchase Agreement with Lincoln Park Capital Fund, LLC on July 21, 2025, providing up to $25.0 million in committed equity financing over a 36-month period.
• As part of the agreement, Cingulate issued 120,424 Commitment Shares to Lincoln Park as a fee, for which no cash consideration was received.
• Cingulate may sell up to an additional 2,379,576 shares of common stock to Lincoln Park, with the purchase price based on market prices at the time of sale.
• The company will not receive any proceeds from Lincoln Park's resale of shares, but will receive proceeds from its direct sales to Lincoln Park under the Purchase Agreement.
• The previous $12.0 million purchase agreement with Lincoln Park Capital expired on June 30, 2025, after being fully utilized.
• As of July 21, 2025, there were 5,146,239 shares of common stock outstanding, including the 120,424 Commitment Shares.
• If all 2,379,576 Purchase Shares were issued, they would represent approximately 33.2% of the total outstanding shares as of July 21, 2025.
• Pro forma adjusted net tangible book value as of March 31, 2025, would be approximately $3.04 per share, representing an immediate dilution of $2.13 per share to new investors assuming a $5.17 purchase price.
• The company anticipates submitting the New Drug Application (NDA) for CTx-1301 by the end of July or early August 2025, following FDA communication that further pediatric and adolescent studies are not required for submission.
• Safety data from two closed Phase 3 trials and a food effect study for CTx-1301 showed no serious treatment emergent adverse events or clinically relevant trends in TEAEs.

Sentiment

Score: 6

Explanation: The filing indicates a crucial financing round that provides significant capital for the company's operations and the advancement of its lead drug candidate towards NDA submission, which is a positive step. However, the substantial dilution potential and the 'going concern' warning from the auditor temper the overall sentiment, indicating ongoing financial challenges despite the new funding.

Positives

• Secured up to $25.0 million in committed equity financing, providing capital for operations and development.
• Anticipated NDA submission for CTx-1301 by end of July or early August 2025, a significant regulatory milestone.
• FDA communication indicates that further pediatric and adolescent studies for CTx-1301 are not required for NDA submission, potentially accelerating the approval process.
• Safety data from CTx-1301 Phase 3 trials showed no serious treatment emergent adverse events, indicating a favorable safety profile.
• Proprietary Precision Timed Release (PTR) drug delivery platform addresses unmet needs in ADHD treatment by aiming for true once-daily dosing with improved side effect profiles.
• Targeting a large and growing U.S. ADHD market, estimated at over $23 billion, with a strong focus on stimulant medications ($18.6 billion segment).

Negatives

• The financing agreement with Lincoln Park Capital Fund, LLC will result in substantial dilution to existing stockholders.
• The company's audit report contains an explanatory paragraph stating that losses and negative cash flows from operations raise substantial doubt about its ability to continue as a going concern.
• The actual number of shares sold and proceeds received from Lincoln Park are uncertain and depend on market prices, which could lead to greater dilution if share prices decline.
• The company will not receive any cash proceeds from the 120,424 Commitment Shares issued to Lincoln Park as a fee.
• Investment in the company's securities is highly speculative and involves a high degree of risk, as stated in the filing.

Risks

• Investment in securities involves a high degree of risk and could result in a loss of the entire investment.
• Inability to predict the actual number of shares sold to Lincoln Park or the gross proceeds due to fluctuating market prices.
• Lincoln Park may sell shares at varying prices, potentially causing a decline in the company's common stock value.
• Limitations on the amount of shares that can be issued to Lincoln Park (e.g., Exchange Cap of 1,004,660 shares or 19.99% without stockholder approval/price threshold, and Beneficial Ownership Cap of 4.99% or 9.99%) may limit the company's ability to fully utilize the $25.0 million commitment.
• Future sales of common stock beyond the currently registered amount would require additional registration, leading to further substantial dilution to stockholders.
• The sale or issuance of common stock to Lincoln Park, or the perception of such sales, could cause the price of common stock to decrease and make it more difficult to raise capital in the future.
• Management has broad discretion over the use of net proceeds, and funds may not be invested successfully.
• The company has a lack of operating history and a need for additional capital.
• Risks related to obtaining and maintaining regulatory approvals for product candidates (CTx-1301, CTx-1302, CTx-2103).
• Risks associated with the timing and success of planned clinical trials.
• Challenges in commercialization, marketing, and manufacturing capabilities and strategy.
• Inability to identify strategic partnerships.
• Impact of laws and regulations on the business.
• Ability to identify, recruit, and retain key personnel.
• Uncertainty regarding the company's status as an emerging growth company.
• Risks related to identifying additional product candidates with significant commercial potential.
• Estimates regarding future revenue and expenses may not be accurate.
• The audit report contains an explanatory paragraph about substantial doubt regarding the company's ability to continue as a going concern due to losses and negative cash flows.

Future Outlook

The company plans to use the proceeds from the Lincoln Park financing to obtain regulatory approval and fund development, manufacturing, and commercialization activities for CTx-1301. It also intends to use funds for working capital, capital expenditures, and general corporate purposes, including further research and development efforts. The New Drug Application (NDA) for CTx-1301 is anticipated to be submitted by the end of July or early August 2025. The company is also identifying and evaluating additional therapeutic areas where its PTR technology may be employed to develop future product candidates beyond ADHD and anxiety.

Industry Context

The company operates in the biopharmaceutical sector, specifically targeting the large and growing ADHD treatment market, which is dominated by stimulant medications. Its Precision Timed Release (PTR) drug delivery platform aims to address existing unmet needs in this market, such as the requirement for multiple daily doses and suboptimal side effect profiles of current extended-release stimulant therapies. By developing true once-daily medications, the company seeks to differentiate itself and capture market share by offering improved patient convenience, reduced abuse potential, and economic benefits for patients and payers.

Comparison to Industry Standards

• The company's CTx-1301 and CTx-1302 candidates aim to provide a near immediate onset of action (within 30 minutes), which is a competitive feature compared to some existing extended-release ADHD medications.
• The goal of providing 'entire active-day duration' and 'eliminating the need for booster/recovery doses' directly addresses a significant shortcoming of current once-daily extended-release dosage forms, where most patients still require a second dose.
• The focus on 'minimizing or eliminating the rebound/crash symptoms' and 'providing favorable tolerability with a controlled descent of drug blood levels' seeks to improve upon the side effect profiles commonly associated with existing stimulant therapies.
• By eliminating booster doses, the company believes its product candidates will reduce abuse and diversion associated with short-acting stimulant medications, allowing physicians to prescribe one medication instead of two, and reducing costs for patients and payers, which could be a significant competitive advantage in the market.

Corporate Governance

Related Party Transactions

• On August 9, 2022, Cingulate Therapeutics LLC issued a $5 million promissory note to Werth Family Investment Associates LLC (WFIA), where Peter J. Werth, a director, is the manager.
• On May 9, 2023, the August Note was amended and restated to increase the principal amount to $8.0 million.
• On August 11, 2023, the company completed a private placement with WFIA, issuing 7,597 shares of common stock for approximately $1.0 million.
• On September 8, 2023, the company and CTx entered into a note conversion agreement with WFIA, converting $5,812,500 (principal and interest) under the Amended and Restated Note into pre-funded warrants (28,493 shares).
• On January 25, 2024, the company and CTx entered into another Note Conversion Agreement with WFIA, converting the remaining $3.0 million principal plus interest ($3,287,500) into pre-funded warrants (57,254 shares).
• On March 25, 2024, an additional 588 pre-funded warrants were issued to WFIA due to an interest calculation error.

Stakeholder Impact

• **Shareholders**: Will experience substantial dilution due to the issuance of new shares under the Lincoln Park Purchase Agreement. The value of their existing holdings could decrease, and their voting and economic interests will be diluted. The 'going concern' warning also poses a risk to their investment.
• **Investors (New)**: Face immediate dilution upon purchasing shares, as the purchase price is higher than the pro forma net tangible book value per share. The speculative nature of the investment and market price fluctuations are significant risks.
• **Company (Cingulate Inc.)**: Benefits from up to $25.0 million in committed equity financing, providing crucial capital for drug development, regulatory submissions, and general operations, addressing immediate liquidity needs and the 'going concern' issue.
• **Lincoln Park Capital Fund, LLC**: Gains the right to purchase shares at a discount to market price and potentially profit from resale, while also receiving Commitment Shares as a fee for its commitment.
• **Patients (ADHD/Anxiety)**: Potential positive impact if CTx-1301 and CTx-1302 successfully gain regulatory approval and offer improved treatment options (once-daily, better side effect profile).
• **Employees**: Continued employment and potential for growth if the company's product pipeline progresses successfully with the new funding.

Next Steps

• Submission of the New Drug Application (NDA) for CTx-1301 by the end of July or early August 2025.
• Potential future sales of common stock to Lincoln Park Capital Fund, LLC under the Purchase Agreement over a 36-month period, subject to market conditions and company discretion.
• Further development, manufacturing, and commercialization activities for CTx-1301.
• Continued investment in research and development efforts.
• Identification and evaluation of additional therapeutic areas for the PTR technology.
• Potential need to register additional shares for resale under the Securities Act if the company elects to sell more than the currently registered shares to Lincoln Park to reach the full $25.0 million commitment.

Key Dates

Recommendation

The filing presents a mixed bag for investors. The securing of $25 million in committed equity financing is a critical positive, providing necessary capital for a biopharmaceutical company with a 'going concern' warning. The anticipated NDA submission for CTx-1301 is a significant near-term catalyst. However, the substantial dilution from the financing, the inherent risks of a development-stage biotech company, and the 'going concern' audit opinion suggest caution. While the long-term potential of the PTR platform and ADHD market is attractive, the immediate financial risks and dilutive nature of the funding warrant a 'hold' recommendation. Investors should monitor the NDA submission outcome and subsequent commercialization efforts closely before considering further investment.

Keywords

Biopharmaceutical, ADHD, Drug Delivery, Precision Timed Release, PTR Technology, CTx-1301, CTx-1302, Dexmethylphenidate, Dextroamphetamine, SEC Filing, S-1/A, Equity Financing, Lincoln Park Capital, Committed Equity, NDA Submission, Clinical Trials, Pharmaceutical Development, Biotech, Nasdaq